Silk Road Medical, Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SILK research report →
Range $20 – $46
Price Chart
About the company
Silk Road Medical, Inc. operates as an American medical device company, focusing on innovative solutions for carotid artery disease. The firm's product portfolio is specifically engineered to support transcarotid artery revascularization (TCAR) procedures.
- CEO
- Charles S. McKhann
- IPO
- 2019
- Employees
- 474
- HQ
- Sunnyvale, CA, US
Get TickerSpark's AI analysis on SILK
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.12B
- P/E
- -19.09
- PEG
- 4.80
- P/S
- 6.31
- P/B
- 7.06
- EV/EBITDA
- -26.21
- Div Yield
- 0.00%
- Gross Margin
- 71.75%
- Op Margin
- -33.46%
- Net Margin
- -31.47%
- ROE
- -35.39%
- ROIC
- -25.04%
Latest fiscal year · YoY change
- Revenue
- $177.13M+27.8%
- Gross Profit
- $127.09M+26.1%
- Op Income
- $-59,271,000
- Net Income
- $-55,743,000+3.9%
- EPS
- $-1.44+11.1%
- OCF Growth
- +1.7%
- FCF Growth
- +10.8%
- 52W High
- $27.51
- 52W Low
- $6.08
- 50D MA
- $27.10
- 200D MA
- $19.85
- Beta
- 1.54
- RSI (14)
- 72
- Avg Volume
- 2.06M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Silk Road Medical delivered strong Q1 2024 revenue growth and margin expansion, but kept full-year guidance unchanged while pointing to early-year uncertainty and launch-related timing effects.· April 30, 2024
- Q1 revenue was $48.5 million, up 21% year over year, with more than 6,725 TCAR procedures, up 15%.
- Gross margin improved to 75% from 69% a year ago, helped by favorable purchase price variances and good execution.
- Adjusted EBITDA loss narrowed to $3.9 million from $7.4 million, and net loss improved to $14.1 million, or $0.36 per share.
- Management said tapered stent and NPS PLUS launches, plus expanded Medicare coverage, are supporting adoption, but some Q1 benefit may have been timing/stocking-related.
- Full-year 2024 revenue guidance stayed at $194 million to $198 million, and management said it will revisit guidance on the Q2 call.
Revenue for the 3 months ended March 31, 2024 was $48.5 million, up 21% from $40.1 million in the same period last year. TCAR procedures were over 6,725 in the quarter, up 15% year over year. Gross margin was 75% versus 69% a year ago. Net loss was $14.1 million, or $0.36 per share, versus a net loss of $16.5 million, or $0.43 per share, last year. Adjusted EBITDA loss was $3.9 million versus $7.4 million in the prior-year period. Cash, cash equivalents and investments were $176.5 million at quarter end. Full-year 2024 revenue guidance remains $194 million to $198 million, implying 10% to 12% growth, and management expects full-year adjusted EBITDA improvement versus 2023. Gross margin is expected to decline modestly in Q2 and then normalize, with a modest full-year improvement versus 2023. Operating expenses are expected to be roughly steady quarter to quarter through the rest of 2024.
Charles McKhann framed the quarter as a strong start to the year and emphasized that TCAR adoption is being driven by clinical evidence, expanded Medicare coverage, and growing awareness among physicians, referring doctors, and patients. He said the company is deepening its commercial base, with more than 2,800 TCAR-trained physicians, and highlighted the 100,000 cumulative patient milestone as proof that TCAR is no longer a new category. His tone was confident and optimistic, but he also stressed that it is still early in the year and that the company wants more runway before changing guidance.
Lucas Buchanan said Q1 revenue growth outpaced procedure growth in part because of the tapered stent launch and stocking dynamics as hospitals establish new par levels, and he expects revenue and procedure growth to vary by quarter. He noted gross margin of 75% was lifted by favorable purchase price variances and prior-year production issues, and he expects a modest Q2 step-down before normalization, with a modest full-year gross margin improvement versus 2023. He also said operating expenses were $51.4 million, with SG&A at $40.8 million and R&D at $10.7 million, and that the company ended with $176.5 million in cash, cash equivalents and investments. He reiterated confidence in achieving profitability with existing capital and in delivering adjusted EBITDA improvement for full-year 2024 relative to 2023.
Analysts focused on why management did not raise guidance after a strong quarter, and McKhann said it is still early, with Q1 being the first full quarter under the new reimbursement environment and with a relatively new sales organization. On pricing and revenue per procedure, Buchanan said ASPs remain strong, but launch-related inventory buildup and changing par levels can create temporary lifts that should normalize over time. Questions also probed whether the NCD is changing competitive dynamics; Buchanan said they are seeing more awareness and some new account openings, but not a big wave of new transforaminal-stenting training. Analysts asked about sales force maturity and gross margin/OpEx cadence; management said reps are progressing well, retention is strong, gross margin should step down in Q2, and OpEx should stay roughly around the current run rate. They also pressed on same-store versus new-account growth and R&D priorities, and McKhann said growth is increasingly coming from the existing installed base while the company remains focused on carotid leadership and is not ready to discuss early pipeline programs in detail.
The bull case from this call is that TCAR adoption is still expanding from a growing base of trained physicians, aided by expanded Medicare coverage and stronger clinical evidence. Management also signaled that new product launches are landing well, margins improved sharply, and the company has enough cash to pursue profitability without raising capital.
The main risks are that some of the quarter’s revenue strength may have been pulled forward by the tapered stent launch and hospital stocking, which could fade in later quarters. Management also acknowledged that Q2 gross margin should step down, full-year guidance was left unchanged despite a strong quarter, and the competitive/training environment remains slow-moving, with no sign yet of a broad shift away from carotid endarterectomy or a major wave into transforaminal stenting.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 92.6%
- Shares Outstanding
- 40.63M
- Float Shares
- 37.63M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.14. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for SILK, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel GoldmanHouse · NY10 | Sell | Mar 6, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 3.37M | ▲ 394.77K |
| Cetera Advisors LLC | 38.76K | ▲ 38.76K |
Held by 2 ETFs
Biggest fund positions in SILK by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 17, 24 | Zurbay Donald | sell | 29,206 |
| Sep 17, 24 | Zurbay Donald | sell | 12,610 |
| Sep 17, 24 | Zurbay Donald | sell | 8,910 |
| Sep 17, 24 | Zurbay Donald | sell | 146,031 |
| Sep 17, 24 | WEATHERMAN ELIZABETH H | sell | 35,185 |
| Sep 17, 24 | WEATHERMAN ELIZABETH H | sell | 8,910 |
| Sep 17, 24 | WEATHERMAN ELIZABETH H | sell | 155,004 |
| Sep 17, 24 | LASERSOHN JACK W | sell | 8,910 |
| Sep 17, 24 | LASERSOHN JACK W | sell | 16,735 |
| Sep 17, 24 | Chou Tony M. | sell | 8,910 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SILK coverage
Recent articles, reports, and earnings notes.
No research on SILK yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SILK report →Boston Scientific Announces Results for Third Quarter 2024
prnewswire.com · Oct 23
Boston Scientific Closes Acquisition of Silk Road Medical, Inc.
prnewswire.com · Sep 17
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BALY and SILK on Behalf of Shareholders
accesswire.com · Aug 22
SILK INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Merger and Looming Vote on September 5, 2024, of Silk Road Medical, Inc.
globenewswire.com · Aug 21
SILK INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Merger and Looming Vote on September 5, 2024, of Silk Road Medical, Inc.
prnewswire.com · Aug 20
SILK Alert: Monsey Firm of Wohl & Fruchter Renews Investigation of the Proposed Sale of Silk Road Medical to Boston Scientific
globenewswire.com · Aug 19
Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates
zacks.com · Aug 7
Silk Road Medical Celebrates Milestone of 100,000 Transcarotid Artery Revascularization (TCAR) Procedures
globenewswire.com · Jul 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.